Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties
Copyright © 2023 IBRO. Published by Elsevier Ltd. All rights reserved..
Subjective cognitive decline (SCD) and objective subtle cognitive difficulties (Obj-SCD) are considered the initial stages of aberrant cognition prior to mild cognitive impairment (MCI) due to Alzheimer's disease (AD). We aimed to determine the difference of brain function of SCD and Obj-SCD, furthermore, to figure out which one could be the marker of early AD. One hundred and eighty-five participants were enrolled in this study to determine the amyloid pathology and glucose metabolism changes in SCD and Obj-SCD. The association of amyloid deposition and glucose metabolism with cognitive domains were also investigated. Obj-SCD displayed significantly increased amyloid deposition in frontal and temporal lobes compared to SCD and normal cognitive control (NCC). No difference of amyloid deposition between SCD and NCC, and no difference of glucose metabolism among the three groups were observed. Amyloid deposition was associated with function of memory, language and executive domains, and glucose metabolism was only associated with executive function in Obj-SCD. Amyloid deposition was only associated with executive function in SCD. Obj-SCD could be the early stage of AD, which displayed significant increased amyloid deposition, and the increased amyloid deposition was associated with cognitive function in different domains.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:513 |
|---|---|
| Enthalten in: |
Neuroscience - 513(2023) vom: 01. März, Seite 137-144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ren, Shuhua [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amyloid beta-Peptides |
|---|
| Anmerkungen: |
Date Completed 28.02.2023 Date Revised 01.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neuroscience.2023.01.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351458603 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351458603 | ||
| 003 | DE-627 | ||
| 005 | 20231226051420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neuroscience.2023.01.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351458603 | ||
| 035 | |a (NLM)36634906 | ||
| 035 | |a (PII)S0306-4522(23)00008-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ren, Shuhua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2023 | ||
| 500 | |a Date Revised 01.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 IBRO. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a Subjective cognitive decline (SCD) and objective subtle cognitive difficulties (Obj-SCD) are considered the initial stages of aberrant cognition prior to mild cognitive impairment (MCI) due to Alzheimer's disease (AD). We aimed to determine the difference of brain function of SCD and Obj-SCD, furthermore, to figure out which one could be the marker of early AD. One hundred and eighty-five participants were enrolled in this study to determine the amyloid pathology and glucose metabolism changes in SCD and Obj-SCD. The association of amyloid deposition and glucose metabolism with cognitive domains were also investigated. Obj-SCD displayed significantly increased amyloid deposition in frontal and temporal lobes compared to SCD and normal cognitive control (NCC). No difference of amyloid deposition between SCD and NCC, and no difference of glucose metabolism among the three groups were observed. Amyloid deposition was associated with function of memory, language and executive domains, and glucose metabolism was only associated with executive function in Obj-SCD. Amyloid deposition was only associated with executive function in SCD. Obj-SCD could be the early stage of AD, which displayed significant increased amyloid deposition, and the increased amyloid deposition was associated with cognitive function in different domains | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Amyloid deposition | |
| 650 | 4 | |a Glucose metabolism | |
| 650 | 4 | |a Objective subtle cognitive difficulties | |
| 650 | 4 | |a Subjective cognitive decline | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 700 | 1 | |a Li, Junpeng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Kewei |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Jingchao |e verfasserin |4 aut | |
| 700 | 1 | |a Jessen, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Xiaochen |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Donglang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaomin |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Yihui |e verfasserin |4 aut | |
| 700 | 1 | |a Hua, Fengchun |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Qihao |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Fang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuroscience |d 1976 |g 513(2023) vom: 01. März, Seite 137-144 |w (DE-627)NLM000132403 |x 1873-7544 |7 nnns |
| 773 | 1 | 8 | |g volume:513 |g year:2023 |g day:01 |g month:03 |g pages:137-144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neuroscience.2023.01.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 513 |j 2023 |b 01 |c 03 |h 137-144 | ||